Furthermore, this review connects glial cytokine patterns to validated and emerging biomarkers—GFAP and NfL in biofluids, and TSPO-PET and QSM for imaging—outlining how these markers can guide patient stratification and endpoint selection in PMS clinical trials [13,14]. This evidence concerns the gene NEFL and premenstrual tension.